

Indication	EudraCT/CT.gov Number	Trial Short Desc	Start Date	Phase	Development Name	Summary/Results
Dermatosis, steroid-re	H0411	Bioavailability top. corticosteroid in vasoconstr. assay	01/04/2004	Phase I	Laticort	AVAILABLE
Dermatosis, steroid-re	H0410	Dermal tolerance of topical formulations	14/04/2004	Phase I	Laticort	AVAILABLE
Hay Fever (Seasonal A	2004-00163-16	Ebastine 20mg FD vs Desloratadine 5 mg Inhibitory effect on	07/04/2005	Phase I	EBASTINE	AVAILABLE
Migraine	2005-000244-90	Almotriptan in Menstrual Migraine	31/05/2005	Phase IV Glc	ALMOTRIPTAN	AVAILABLE
Hay Fever (Seasonal A	2004-005162-21	inhibitory effect of Ebastine 10 mg	17/06/2005	Phase I	EBASTINE	AVAILABLE
Migraine	2004-005285-20	Almotriptan in mild pain vs. moderate to severe pain	11/07/2005	Phase IV Glc	ALMOTRIPTAN	AVAILABLE
Verrucea vulgaris	2005-001593-26	Verrucea vulgaris in organtransplant recipients	10/08/2005	Phase IV Glc	LAS41005	AVAILABLE
Psoriasis	2005-003161-16	Safety, tolerability, PK, single and multiple doses. healthy	01/11/2005	Phase I	LAS37779	AVAILABLE
Psoriasis Plaque	2005-003163-23	Atrophogenic potential and dermal tolerance of LAS37779	02/11/2005	Phase I	LAS37779	AVAILABLE
Psoriasis Plaque	2005-003162-42	Efficacy, safety and tolerability of 1% LAS37779 cream	03/11/2005	Phase IIa	LAS37779	AVAILABLE
Gastric upset	2005-001184-54	Preference study: orodispersible tablets vs capsules	02/12/2005	Phase IV Glc	LANSOPRAZOLE	AVAILABLE
Psoriasis	2005-004332-51	Topical corticosteroids in vasoconstrictor assay	19/12/2005	Phase I	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2005-004331-22	Tolerability topical formulations non-occlusive application	23/01/2006	Phase I	MOMETASONE FUROATE	AVAILABLE
Asthma	2006-000334-12	Protective Effect of Montelukast in AMP-induced BHR in asthm	23/03/2006	Phase I	MONTELUKAST	AVAILABLE
Hay Fever (Seasonal A	2006-002936-13	Bioequivalence (10 mg tablets) of Ebastine in healthy sub.	12/07/2006	Phase I	EBASTINE	AVAILABLE
Psoriasis Plaque	2006-001126-90	Curatoderm in plaque psoriasis	01/09/2006	Phase III	tacalcitol	AVAILABLE
Acne	2006-003594-27	Tolerability of Adapalene and BPO, different concentrations	20/11/2006	Phase I	Adapalene combinations	AVAILABLE
Psoriasis	2006-003598-28	Bioavailability of topical corticosteroid formulations	27/11/2006	Phase I	MOMETASONE FUROATE	AVAILABLE
Dermatosis, steroid-re	2006-03600-19	Topical corticosteroids in vasoconstrictor assay	10/01/2007	Phase I	Laticort	AVAILABLE
Psoriasis	2006-003601-10	Skin thickness under topical steroid/retinoid	15/01/2007	Phase I	LAS41004	AVAILABLE
Dermatosis, steroid-re	2006-003599-36	Tolerability of topical Laticort formulations	01/02/2007	Phase I	Laticort	AVAILABLE
Rosacea	2006-002410-35	Isotretinoin versus doxycycline in the treatment of rosacea	13/02/2007	Phase II	Isotretinoin	AVAILABLE
Actinic Keratosis	2006-005432-24	Efficacy and tolerability of Verrumal in actinic keratosis	19/04/2007	Phase II	LAS41005	AVAILABLE
Acne	2006-005433-38	Irritation potential of Adapalene and BPO, diff. concentr.	23/04/2007	Phase I	Adapalene combinations	AVAILABLE
Psoriasis Plaque	2007-001793-87	Efficacy and Safety of LAS37779 1% Cream in Plaque Psoriasis	03/08/2007	Phase IIa	LAS37779	AVAILABLE
Asthma	2007-000220-40	Safety, tolerability, PK of A2B receptor antagonist LAS10105	07/08/2007	Phase I	LAS101057	AVAILABLE
Psoriasis	2007-004287-46	Bioavailability of topical corticosteroid formulation	04/12/2007	Phase I	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2007-004264-48	Tolerance mometasone repeated application	28/01/2008	Phase I	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2007-007828-18	Bioavailability topical corticosteroids in vasoconstric assay	02/04/2008	Phase I	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2007-007829-42	Antipsoriatic effect of topical formulations psoriasis test	19/05/2008	Phase I	LAS41004	AVAILABLE
Psoriasis	2007-007827-42	Dermal tolerability of top. mometasone cream on intact skin	19/05/2008	Phase I	MOMETASONE FUROATE	AVAILABLE
Actinic Keratosis	2007-003889-18	Verrumal vs. placebo vs. Solaraze in Actinic Keratosis I/II	05/06/2008	Phase III	LAS41005	AVAILABLE
Psoriasis	2008-002141-24	Anti-psoriatic efficacy in a psoriasis plaque test	23/06/2008	Phase II	MOMETASONE FUROATE	AVAILABLE

Indication	EudraCT/CT.gov Number	Trial Short Desc	Start Date	Phase	Development Name	Summary/Results
Not applicable	2008-000253-34	Safety, Tolerability, PK and Dynamics of LAS186323	12/08/2008	Phase I	LAS186323	AVAILABLE
Eczema	2008-003361-11	Dermal tolerability of topical LAS41003 on intact skin	22/09/2008	Phase I	LAS41003	AVAILABLE
Infected Eczema	2008-003362-26	Antimicrobial efficacy of topical octenidine/prednicarbonate	29/09/2008	Phase IIa	LAS41003	AVAILABLE
Psoriasis	2008-001979-30	Bioequivalence DMF/ethylhydrogenfumarate vs. Fumaderm	24/10/2008	Phase I	LAS190046	AVAILABLE
Psoriasis	2008-001980-12	Bioequivalence DMF/ethylhydrogenfumarate vs. Fumaderm	04/11/2008	Phase I	LAS190046	AVAILABLE
Psoriasis	2008-007288-18	Irritation potential mometasone lotion comparison	23/02/2009	Phase I	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2008-007289-40	Analysis of the efficacy of 0.1% mometasone furoate	30/03/2009	Phase I	MOMETASONE FUROATE	AVAILABLE
Eczema	2009-009949-42	Bioavailability in vasoconstrictor assay	23/04/2009	Phase I	LAS41003	AVAILABLE
Eczema	2009-009946-18	Tolerability LAS41003 on repeated application	27/04/2009	Phase I	LAS41003	AVAILABLE
Infected Eczema	2009-009948-23	Antimicrobial efficacy of topical LAS41003 in exp.flora test	02/06/2009	Phase IIa	LAS41003	AVAILABLE
Actinic Keratosis	2009-012063-33	LAS41007 vs. Solaraze in actinic keratosis I&II	12/08/2009	Phase II	LAS41007	AVAILABLE
Infected Eczema	2009-011931-11	Efficacy and Safety of topically applied LAS41003	06/11/2009	Phase II	LAS41003	AVAILABLE
Scalp Psoriasis	2009-016261-28	Efficacy of LAS41002 lotion in scalp psoriasis	07/01/2010	Phase IIb	MOMETASONE FUROATE	AVAILABLE
Tinea pedis	2009-016626-14	Treatment Efficacy& Safety of Inflammatory Tinea Pedis	01/02/2010	Phase II	LAS41003	AVAILABLE
Tinea pedis	2009-016626-14	Antimicrobial efficacy of topical octenidine/prednicarbonate	03/02/2010	Phase IIa	LAS41003	AVAILABLE
Candida Infection	2009-016627-56	Antimycotic efficacy of topical LAS41003	10/02/2010	Phase IIa	LAS41003	AVAILABLE
Atopic eczema	2009-017407-28	Mometasone/LAS41002 in atopic eczema	10/02/2010	Phase II	MOMETASONE FUROATE	AVAILABLE
Psoriasis Plaque	2009-016629-33	Efficacy of LAS41002 lotion in a psoriasis plaque test	22/02/2010	Phase II	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2010-019212-20	Bioequivalence DMF/ethylhydrogen vs. Fumaderm	27/04/2010	Phase I	LAS190046	AVAILABLE
Psoriasis	2010-019213-19	Bioequivalence DMF/ethylhydrogenfumarate vs. Fumaderm	11/05/2010	Phase I	LAS190046	AVAILABLE
Psoriasis Plaque	2010-018355-10	Different concentrations in psoriasis plaque test	28/06/2010	Phase II	LAS41004	AVAILABLE
Actinic Keratosis	2010-022244-20	Efficacy and safety of LAS41007 in actinic keratosis	11/11/2010	Phase III	LAS41007	AVAILABLE
Psoriasis	2010-023301-35	Bioequivalence DMF compared to Fumaderm	20/12/2010	Phase I	LAS190046	AVAILABLE
Psoriasis	2010-023302-12	Bioequivalence DMF/ethylhydrogenfumarate vs. Fumaderm	10/01/2011	Phase I	LAS190046	AVAILABLE
Psoriasis	2010-022281-27	Efficacy of LAS41004 in different formulations	10/01/2011	Phase II	LAS41004	AVAILABLE
Actinic Keratosis	2010-022980-37	Efficacy of LAS41005 compared to cryotherapy	13/04/2011	Phase II	LAS41005	AVAILABLE
Psoriasis Plaque	2011-000186-13	Different formulations of LAS41004 in psoriasis plaque test	02/05/2011	Phase II	LAS41004	AVAILABLE
Not applicable	2011-000389-37	PK after a SD with and without charcoal	09/05/2011	Phase I	LAS40468	AVAILABLE
Psoriasis	2011-001384-45	Antipsoriatic efficacy of retinoid/steroid in Psoriasis test	10/08/2011	Phase I	LAS41004	AVAILABLE
Psoriasis	2011-001380-47	Pharmacokinetics of DMF 30mg vs. Fumaderm	16/09/2011	Phase I	LAS190046	AVAILABLE
Psoriasis	2011-001381-18	Pharmacokinetics of DMF 120mg vs. Fumaderm	21/09/2011	Phase I	LAS190046	AVAILABLE
Not applicable	2011-006153-29	PK fixed dose combination (LABA + ICS)	20/03/2012	Phase I	LAS40468	AVAILABLE
Multiple Sclerosis	2011-002258-30	Sativex on Spasticity in Progressive MS	19/04/2012	Phase III	SATIVEX	AVAILABLE

Indication	EudraCT/CT.gov Number	Trial Short Desc	Start Date	Phase	Development Name	Summary/Results
Psoriasis Plaque	2011-005883-10	Safety and efficacy of topical LAS186323	20/09/2012	Phase I	LAS186323	AVAILABLE
Not applicable	2012-003377-26	PK of FDC delivered by two different inhalers	07/01/2013	Phase I	LAS40468	AVAILABLE
Psoriasis Plaque	2012-000055-13	Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo	18/01/2013	Phase III	LAS190046	AVAILABLE
Asthma/COPD	2013-002816-29	Equivalence of bronchoprotection from methacholine challenge	02/10/2013	Phase I	LAS40468	AVAILABLE
Asthma/COPD	2013-002939-25	PD bronchodilation in asthma patients	29/11/2013	Phase I	LAS40468	AVAILABLE
Nail Psoriasis	2013-004519-28	A phase II trial to evaluate the anti-psoriatic efficacy	07/02/2014	Phase II	LAS41006	AVAILABLE
Psoriasis Plaque	2013-003754-24	Anti-psoriatic efficacy of LAS41004 formulations	24/02/2014	Phase IIa	LAS41004	AVAILABLE
Psoriasis Plaque	2013-003757-22	Antipsoriatic efficacy and safety of LAS41004	02/06/2014	Phase IIa	LAS41004	AVAILABLE
Asthma	2014-001768-36	Salmeterol bronchodilation effect	28/07/2014	Phase I	LAS40468	AVAILABLE
Onychomycosis	2013-005595-17	Paediatric trial on onychomycosis	26/08/2014	Phase II	P-3058 (terbinafine 10% nail sc	AVAILABLE
Actinic Keratosis	2014-001171-31	Field-Directed Treatment Of Actinic Keratoses Grade I to II	17/10/2014	Phase III	ACTIKERALL	AVAILABLE
Onychomycosis	2015-000561-31	Efficacy and Safety of P-3058 10% Nail Sol. in Onychomycosis	20/08/2015	Phase III	P-3058 (terbinafine 10% nail sc	NOT AVAILABLE
Actinic Keratosis	SEQ TREAT AT	NIS Sequential Treatment Actikerall + Solaraze	15/10/2015	Phase IV Loc	ACTIKERALL	AVAILABLE
Nail Psoriasis	2015-002365-34	Efficacy, safety and tolerability of topical P-3073	23/11/2015	Phase III	P-3073 (Calcipotriene 0.005%)	AVAILABLE
Multiple Sclerosis	2015-004451-40	Sativex as add-on therapy vs. further optimized first-line	25/04/2016	Phase IV Glc	SATIVEX	AVAILABLE
Multiple Sclerosis	ESTEEM	Retrospective study-MS resistant spasticity p.(ESTEEM study)	01/05/2016	Phase IV Loc	SATIVEX	AVAILABLE
Pemphigus Vulgaris (P	2015-001068-20	M-191954-01 part I (Single Ascending Dose)	04/05/2016	Phase I	ADP31415	NOT AVAILABLE
Androgenetic Alopecia	2015-004564-11	Photosensitization study in Androgenetic Alopecia	09/05/2016	Phase I	P-3074 (Finasteride 0.25% topi	NOT AVAILABLE
Multiple Sclerosis	M/SATIVX/06	ADL study_Sativex in Activity Daily Living	25/07/2016	Phase IV Glc	SATIVEX	AVAILABLE
Androgenetic Alopecia	2015-002877-40	Efficacy and Safety of P-3074 Topical Solution	02/08/2016	Phase III	P-3074 (Finasteride 0.25% topi	AVAILABLE
Psoriasis	2016-002314-50	PK study of LAS41008 120mg and Fumaderm 120mg in healthy sub	09/09/2016	Phase I	LAS190046	NOT AVAILABLE
Pemphigus Vulgaris (P	2015-001068-20	M-191954-01 part II (Multiple Ascending Dose)	19/09/2016	Phase I	ADP31415	NOT AVAILABLE
Multiple Sclerosis	M/SATIVX/05	TASTE study_Palatability and oral cavity tolerability	21/09/2016	Phase IV Glc	SATIVEX	AVAILABLE
Atopic Dermatitis in Pe	M/000MO/02	Monovo in AD in children	31/01/2017	Phase IV Glc	MOMETASONE FUROATE	AVAILABLE
Psoriasis	2017-001368-40	DIMESKIN 1	06/10/2017	Phase IV Loc	LAS190046	AVAILABLE
Multiple Sclerosis	NIS-BE	Retrospective data collection on MS patients in Belgium	01/01/2018	Phase IV Loc	SATIVEX	AVAILABLE
Psoriasis	SKILL	SKILL – SKILarence® in Long-Term Treatment	31/01/2018	Phase IV Loc	LAS190046	NOT AVAILABLE
Muscle Spasm	2016-001034-10	Neurophysiological effect of Sativex-spasticity after stroke	02/05/2018	IIS Local	SATIVEX	NOT AVAILABLE
Psoriasis	2017-003818-11	DIMESKIN2	31/05/2018	Phase IIIb Lc	LAS190046	NOT AVAILABLE
Multiple Sclerosis		Nursing's role in spasticity detection in MS	29/06/2018	IIS Local	SATIVEX	NOT AVAILABLE
Actinic Keratosis		Lymphocytic inflammatory infiltrate-skin carcinoma	30/07/2018	IIS Global	ACTIKERALL	NOT AVAILABLE
Multiple Sclerosis	SATKAM	Evaluación del dispositivo de administración de Sativex	08/10/2018	Phase IV Glc	SATIVEX	AVAILABLE
Psoriasis	T1801	TILOT - Tildrakizumab (Ilumetri) in Long-Term Treatment	08/01/2019	Phase IV Loc	Ilumetri	NOT AVAILABLE

Indication	EudraCT/CT.gov Number	Trial Short Desc	Start Date	Phase	Development Name	Summary/Results
Multiple Sclerosis		MS spasticity numeric ultrasound evaluation	13/03/2019	IIS Global	SATIVEX	NOT AVAILABLE
Multiple Sclerosis	M/SATIVX/08	Sativex and Goal Attainment Scales - GAS Study	28/03/2019	Phase IV Glc	SATIVEX	AVAILABLE
Psoriasis		Effects of DMF treatment in psoriasis (Stigmatization)	01/04/2019	IIS Global	LAS190046	NOT AVAILABLE
Rosacea		A pilot study on the use of Seysara for Rosacea	15/07/2019	IIS Local	SARECYCLINE	NOT AVAILABLE
Psoriasis	2018-004010-18	Efficacy and safety of DMF in plaque Pso patients. MODERATES	06/08/2019	Phase IV Loc	LAS190046	NOT AVAILABLE
Psoriasis	2018-004010-18	Moderate exploratory Sub Study	06/08/2019	Phase IV Glc	LAS190046	NOT AVAILABLE
Psoriasis	UPSKIL	UPSKIL-SKILarence in plaque pso pts meeting Upgrade criteria	15/08/2019	Phase IV Loc	LAS190046	NOT AVAILABLE
Psoriasis	2019-000817-35	Transition DMF to Tildrakizumab	04/09/2019	Phase IV Glc	Ilumetri	AVAILABLE
Psoriasis	NCT04203693	SAIL	30/10/2019	Phase IV Glc	Ilumetri	NOT AVAILABLE
Psoriasis Plaque	2019-002804-42	TRIBUTE (Quality of Life 100mg)	17/12/2019	Phase IV Glc	Ilumetri	AVAILABLE
Psoriasis		DMF in elderly psoriasis patients: a pilot study	15/01/2020	IIS Local	LAS190046	NOT AVAILABLE
Psoriasis	2019-003218-15	MODIFY - Disease-modifying effect of long-term treatment	29/01/2020	Phase IV Glc	Ilumetri	AVAILABLE
Psoriasis		Early Detection & Progression of Subclinic Atherosclerosis.	30/01/2020	IIS Local	Ilumetri	NOT AVAILABLE
Actinic Keratosis		Early response of 5-FU in the treatment of AK (AKASI)	28/02/2020	IIS Local	ACTIKERALL	NOT AVAILABLE
Psoriasis		Biomarkers to predict tildrakizumab response in Pso patients	06/03/2020	IIS Global	Ilumetri	NOT AVAILABLE
Actinic Keratosis		IL-17 and angiogenesis in non-melanoma skin cancer	20/04/2020	IIS Global	ACTIKERALL	NOT AVAILABLE
Psoriasis		Psoriasis in older adults (geriatric patients)_retrospective	22/04/2020	IIS Global	LAS190046	NOT AVAILABLE
Muscle Spasm		Spasticity control with Sativex® in patients with MSS in AU	09/06/2020	Phase IV Loc	SATIVEX	NOT AVAILABLE
Bronchitis	NCT04322669	Pidotimod in children with respiratory infections P-CRESCENT	13/08/2020	Phase IV Glc	Pidotimod	NOT AVAILABLE
Nail Psoriasis	H1902	Effectiveness of Tildra in nail/pso patients in RWC - TINAIL	16/10/2020	Phase IV Loc	Ilumetri	NOT AVAILABLE
Multiple Sclerosis		Tele-rehabilitation in combination with Sativex	01/02/2021	IIS Local	SATIVEX	NOT AVAILABLE
Psoriasis		FAEs can down-regulate INF-inducible chemokines CXCL9/10/11	01/02/2021	IIS Local	LAS190046	NOT AVAILABLE
Psoriasis		Tildra tx. on carotid intima-media thickness in Pso patients	24/02/2021	IIS Local	Ilumetri	NOT AVAILABLE
Multiple Sclerosis		Spasticity on upper limb function in people with MS	01/03/2021	IIS Local	SATIVEX	NOT AVAILABLE
Atopic Dermatitis	2021-002967-23	Cyclosporine failure Phase III study	25/01/2022	Phase III	Lebrikizumab	NOT AVAILABLE
Actinic Keratosis	NCT05279131	Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants W	28/06/2022	Phase III	Tirbanibulin	NOT AVAILABLE
Actinic Keratosis	NCT05387525	Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp	24/10/2022	Phase IV	Tirbanibulin	NOT AVAILABLE
Atopic Dermatitis	NCT05916365	Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant W	23/05/2023	Phase III	Lebrikizumab	NOT AVAILABLE
Atopic Dermatitis	NCT05990725	Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolesc	20/11/2023	Phase 3B	Lebrikizumab	NOT AVAILABLE
Actinic Keratosis	NCT06135415	Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Act	21/12/2023	Phase III	Tirbanibulin	NOT AVAILABLE
Atopic Dermatitis	NCT06526182	Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Der	03/07/2024	Phase IIIb	Lebrikizumab	NOT AVAILABLE